Polymorphism between HLA-A*0301 and A*0302 located outside the pocket F alters the PΩ peptide motif

Tissue Antigens

Volumn 76, Issue 6, 2010, Pages 487-490

  Elamin, N E ^a   Bade Doeding, C ^a   Blasczyk, R ^a   Eiz Vesper, B ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Auxiliary anchor; Peptide binding motif; Polymorphism; Stem cell transplantation

Indexed keywords

GLUTAMIC ACID; GLYCINE; HLA A ANTIGEN; LEUCINE; VALINE; HLA A*03:01 ANTIGEN; HLA-A*03:01 ANTIGEN; PEPTIDE;

ALLELE; ARTICLE; CONTROLLED STUDY; GENETIC POLYMORPHISM; HLA SYSTEM; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF; SUDAN; AMINO ACID SUBSTITUTION; GENETICS; IMMUNOLOGY;

ALLELES; AMINO ACID MOTIFS; AMINO ACID SUBSTITUTION; HLA-A ANTIGENS; HUMANS; PEPTIDES; SUDAN;

EID: 78149401671     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2010.01547.x     Document Type: Article

References (17)

1. Tynan FE, Burrows SR, Buckle AM et al. T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide. Nat Immunol 2005: 6: 1114-22.
2. Burrows JM, Bell MJ, Brennan R, Miles JJ, Khanna R, Burrows SR. Preferential binding of unusually long peptides to MHC class I and its influence on the selection of target peptides for T cell recognition. Mol Immunol 2008: 45: 1818-24.
3. Bell MJ, Burrows JM, Brennan R et al. The peptide length specificity of some HLA class I alleles is very broad and includes peptides of up to 25 amino acids in length. Mol Immunol 2009: 46: 1911-7.
4. Chelvanayagam G. A roadmap for HLA-A, HLA-B, and HLA-C peptide binding specificities. Immunogenetics 1996: 45: 15-26.
5. Saper MA, Bjorkman PJ, Wiley DC. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution. J Mol Biol 1991: 219: 277-319.
6. Macdonald WA, Purcell AW, Mifsud NA et al. A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition. J Exp Med 2003: 198: 679-91.
7. *30 allelic group. Tissue Antigens 2000: 56: 10-8.
8. Prilliman KR, Jackson KW, Lindsey M, Wang J, Crawford D, Hildebrand WH. HLA-B15 peptide ligands are preferentially anchored at their C termini. J Immunol 1999: 162: 7277-84.
9. *6601 ligands. Immunogenetics 2004: 56: 83-8.
10. *41 variants. Immunogenetics 2007: 59: 253-9.
11. Fleischhauer K, Kernan NA, O'Reilly RJ, Dupont B, Yang SY. Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44. N Engl J Med 1990: 323: 1818-22.
12. Keever CA, Leong N, Cunningham I et al. HLA-B44-directed cytotoxic T cells associated with acute graft-versus-host disease following unrelated bone marrow transplantation. Bone Marrow Transplant 1994: 14: 137-45.
13. Hirosawa M, Hoshida M, Ishikawa M, Toya T. MASCOT: multiple alignment system for protein sequences based on three-way dynamic programming. Comput Appl Biosci 1993: 9: 161-7.
14. DiBrino M, Parker KC, Shiloach J et al. Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides. Proc Natl Acad Sci U S A 1993: 90: 1508-12.
15. Kruger T, Schoor O, Lemmel C et al. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother 2005: 54: 826-36.
16. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991: 351: 290-6.
17. Burrows SR, Rossjohn J, McCluskey J. Have we cut ourselves too short in mapping CTL epitopes? Trends Immunol 2006: 27: 11-6.